This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Additional information regarding cannabinoids and pain appears online h ere.
CBN has made headlines and claimed shelf space as the next best cannabinoid for sleep. MoreBetter, creators of the Releaf App, is using this real world data to push back against the claim that there’s no evidence that CBN can help people sleep. While CBN is often marketed as “the sleep cannabinoid ,” the reality is more complicated.
The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds.
We are delighted by today’s decision from the MHRA for this new indication, which represents a significant step forward for TSC patients in the UK, many of whom may benefit from this new treatment,” said Chris Tovey , Executive Vice President, Chief Operating Officer and Managing Director, Europe & International at Jazz Pharmaceuticals.
SOURCE InMed Pharmaceuticals Inc. About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need.
million people across the United States , report experiencing improved quality of life and a more restful night’s sleep after consuming the non-psychoactive cannabinoid CBD (cannabidiol). This, the authors say, “is well below the dose commonly associated with pharmaceutical products (e.g. CBD, which constitutes a $2,770.8
Goldstein will be leading the Medical Practicum at CannMed 2023 (May 15-17), where she will also be speaking about CBG and other minor cannabinoids during the main session. You have said that cannabigerol, or CBG, is one of your favorite cannabinoids. Is that because CBG is a precursor for the other plant cannabinoids?
Oxford Cannabinoid Technologies Holdings plc. After confirmation of 6-months stability of tech-transfer batch, the work has been initiated, with preliminary data packages available by the second half of September, well within the proposed timelines. Pre-Close Trading Update; US OTC QB Market Application. &
There are currently five “pharmaceutical processor” permit holders in Virginia, and they’re about to open for business. ” and “We only want to see data from an American source.” There are some minimum and maximum cannabinoid contents with the program.
AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. We were able to rapidly incorporate the FDA’s feedback into the design of the current Phase 2 trial to make the data generated in Europe as relevant as possible for a potential future NDA submission. About Anebulo Pharmaceuticals, Inc.
THE Chairman of a recently-listed UK pharmaceutically-focused cannabis company has stood down after a breach of market rules. Neil Mahapatra is a co-founder of the Oxford Cannabinoid Technologies (OCT) which floated on the LSE in the May this year, he is also founder of UK venture capital business Kingsley Capital Partners (KCP).
This export also validates the emergence of the global cannabinoid sector with reliance on quality, traceability and sustainability that Avicanna ’s Aureus products offer. To the knowledge of the Company, it carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.
Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.
With Avicanna’s dedication to quality standards and pharmaceutical positioning we are poised to be a significant long-term player in the European medical market that is predominantly focused on medical utility of cannabinoids and where meeting EU pharmacopeia standards are essential.”.
Currently, seven of Canada’s top ten cannabis patent holders are major multi-national pharmaceutical companies, according to a joint research project by Washington D.C.-based based New Frontier Data and London-based cannabis bio-technology firm, Grow Biotech. As we’ve referenced before , data shows that the number of U.S.
They require a process in which THC or other cannabinoid particles are reduced to nanoscopic size that allows them to then be mixed with water or other aqueous liquids. There is not extensive safety data available, however. The nanoemulsion method ALT uses is effective for all cannabinoids, not only THC, he said. Shutterstock).
AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announced today that it has appointed Scott L. About Anebulo Pharmaceuticals, Inc.
AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. 11,141,404, titled “Formulations And Methods For Treating Acute Cannabinoid Overdose.” ” The patent provides protection through 2040 and describes use of the Company’s investigational drug ANEB-001 to treat acute cannabinoid overdose.
The EFSA guidance on cannabinoids strongly echoes the U.S. Although the UK recently severed its ties with the European Union, the FSA has opted to align its policy with that of the European Food Safety Authority (“ EFSA ”).
NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, and Biopharmaceutical Research Company (“BRC”), a specialty pharmaceutical company that holds federal licenses for importing, analyzing and manufacturing controlled substances in the U.S.,
Unfortunately, most traditional pharmaceutical options are distinctly lacking due to side effects, as well as a bit of trepidation (although Botox, one current treatment option for migraines, has gained popularity). Patients used the app, Strainprint, which allowed data to be archived and studied.
Most commonly, pharmaceutical medication is prescribed to regulate moods. However, pharmaceutical medications can have side effects, and they may take longer to work for many patients. Thus, this groundbreaking study laid the foundation for understanding how cannabinoids can support mental health.
Even though cannabis and cannabinoid-derived pharmaceuticals are both frequently used by HIV/AIDS patients, several studies show that something interesting happens when cannabis is consumed. How classical pharmaceuticals fight HIV. What is HIV and how is it manifested? There are many different cell types in the human body.
Some researchers believe that cannabinoids may help people with ASD manage anxiety and stress by increasing their ability to focus and pay attention. Cannabinoids have been shown to help people with autism manage anxiety and stress.
HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Consumers spent roughly $31.3 increase in annual sales. 2 The seeds of C.
12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Forward-looking statements.
Cannabidiol (CBD) belongs to a class of molecules called cannabinoids , which are produced almost exclusively in cannabis — hence the name. The two cannabinoids can also cause very different effects in other ways. CBD is also often compared to CBG (cannabigerol) , another increasingly popular cannabinoid. CBD vs CBDA.
In the novel study conducted by researchers at the University of New Mexico, nearly 2,000 people self-administered cannabis over a three-year period and reported their marijuana use via the Releaf App that was specifically designed for the study’s data collection needs. Furthermore, THC and CBD may have a synergistic effect.
In adults with chronic pain, what are the harms of cannabinoids? In adults with chronic pain, what are the benefits of cannabinoids? Cannabis is a plant loaded with cannabinoids like THC , CBN , CBG , CBD , and others. Medicinal cannabinoid therapies are saving and changing lives for people across America and around the world.
The two active cannabinoids in marijuana are cannabidiol (CBD) and tetrahydrocannabinol (THC), the latter of which causes psychoactive effects while the former does not. This system naturally produces cannabinoids in the bloodstream, but chronic stress, anxiety, and other stimuli can stifle the production of natural endocannabinoids.
(“Avicanna”), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products. The Branded Products include Avicanna’s proprietary cannabinoid topical formulations developed through years of extensive research by Avicanna’s team of scientists.
SOURCE InMed Pharmaceuticals Inc. About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need.
Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. Additionally, there are misleading practices of “p-hacking” where researchers can manipulate data through different statistical tests (thanks to modern computer programs) looking for statistically significant findings.
Building the bridge between brands and the marketplace through testing and the importance of good data. A need for data at all of these levels and data specific to product type drives more advanced methodology in the laboratories, often resulting in a better understanding of the matrix and more accurate data.
Mary AG’s joint venture Yunnan Moquan and CBDer are currently the only companies licensed for indoor industrial hemp cultivation in China’s only legalized province for cannabinoid extraction. The MOU mainly encompasses: Working with CBDer to further develop China’s industrial hemp market. About Mary Agrotechnologies Inc.
Data from Colorado, which was among the first states to legalize marijuana, indicates that edible cannabis-infused products account for some 45% of all cannabis sales. These figures do not include homemade edibles made from cannabinoid-infused oils, so the actual percentage of use may be higher!).
The Data and Safety Monitoring Committee (“DSMC”) for IGC’s clinical trial, having reviewed the data obtained through Cohort 1 and Cohort 2, recommended progressing to Cohort 3, which consists of administering three doses per day. Securities and Exchange Commission (“SEC”) on July 13, 2020. About IGC: India Globalization Capital, Inc.
A data firm is warning those infected with the novel coronoavirus to avoid consuming products that contain tetrahydrocannabinol (THC), the main psychoactive component of cannabis. Data CEO Julie Armstrong said her company knows the COVID-19 affects the population in a similar way to influenza. The brief survey can be taken here.
Minor Cannabinoids Market Size, Share & Trends Analysis Report by Product (CBG, CBC, CBN, THCV, CBGA), by Application (Pain Management, Neurological Disorders), and Segment Forecasts, 2021-2028” report has been added to ResearchAndMarkets.com’s offering. minor cannabinoids market size is expected to reach USD 26.2
When antidepressants were first introduced in the mid-20 th century, they were a breakthrough in pharmaceuticals. Though hope remains for using cannabinoids to treat depression, in human studies THC has often been more associated with depressive behavior. But for thousands of people, these little pills aren’t enough.
This is according to recent data from a report published by Market Research Future (MRT) – a pioneer in market analysis. Apart from business leaders, many corporate and government institutions are funding the research and development of cannabinoids for medical applications,” reads an excerpt from the report.
In spite of this, research has shown that THC as much as the other cannabinoids present in cannabis has medicinal value to humans. In the UK, cannabis was legalized for medicinal purposes in 2018 which saw patients of epilepsy and multiple sclerosis able to access pharmaceutical cannabis derivatives such as Sativex and Epidiolex.
– Flora’s research division, Flora Pharma, files USPTO provisional patent application on a cannabinoid-based formula. – Flora seeks approval to take their patent-pending, cannabinoid-based product through clinical trials under an EUA from INVIMA (Colombian FDA).
Brainose is currently developing a pharmaceutical-grade cannabinoid-based therapy with a focus on pain management for FDA and CE approval in the U.S. Indorz : Indoor cannabis farming data solution that predicts, analyzes, and automates the grow process to maximize yield and quality. and Europe. Ag-tech and Growing Solutions.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content